Advice

following a full submission:

cabotegravir (Vocabria®) is accepted for use within NHSScotland.

Indication under review: in combination with rilpivirine prolonged-release injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class

Cabotegravir 600mg prolonged release injection plus rilpivirine 900mg prolonged-release injection every 2-months was non-inferior to cabotegravir 400mg plus rilpivirine 600mg every month in terms of the proportion of patients losing virological suppression in a phase III study. Cabotegravir 400mg prolonged release injection plus rilpivirine 600mg prolonged-release injection was non-inferior to oral antiretroviral therapy.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
cabotegravir (Vocabria)
SMC ID:
SMC2376
Indication:

Cabotegravir long acting (CAB LA) injection is indicated, in combination with rilpivirine long acting (RPV LA) injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.

Pharmaceutical company
ViiV Healthcare
BNF chapter
Infections
Submission type
Full
Status
Accepted
Date advice published
11 October 2021